Skip to main content
SpringerLink
Log in

Impact of Cytogenetics on Outcome of Stem Cell Transplantation for Acute Myeloid Leukemia in First Remission: A Large-Scale Retrospective Analysis of Data from the Japan Society for Hematopoietic Cell Transplantation

  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

On the basis of transplantation data from the Japan Society for Hematopoietic Cell Transplantation, we retrospectively analyzed the impact of cytogenetics at diagnosis on the outcome of transplantation in 628 patients with acute myeloid leukemia who underwent autologous (n = 200), allogeneic related (n = 363), or allogenic unrelated (n = 65) stem cell transplantation (SCT) at first complete remission. For autologous SCT, patients at good cytogenetic risk had a significantly lower relapse rate (P = .017) and a significantly higher event-free survival (EFS) (P = .013) compared with those at intermediate risk. For allogeneic SCT, patients at good cytogenetic risk had a significantly lower relapse rate (P = .019) and insignificantly higher EFS (P = .093) than those at poor risk. For unrelated SCT, there was no significant difference in relapse rate or EFS between patients at good risk and those at intermediate risk. Comparison of the 3 transplantation modalities revealed that autologous SCT patients had a significantly higher incidence of relapse compared with related or unrelated SCT patients in the intermediate-risk group but not in the good-risk group. However, there were no significant differences in EFS among the 3 transplant modalities in either of these 2 risk groups. In multivariate analysis, cytogenetics was found to be an independent predictor of relapse as well as of treatment failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia: results of the Medical Research Council’s 10th AML Trial (MRC AML 10). Blood. 1997;89:2311–2318.

    CAS  PubMed  Google Scholar 

  2. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331:896–903.

    Article  CAS  PubMed  Google Scholar 

  3. Zittoun R, Jehn U, Fiere C, et al. Alternating repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. Blood. 1989;73:896–906.

    CAS  PubMed  Google Scholar 

  4. Cassileth PA, Harrington DP, Hines JD, et al. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol. 1988;6:583–587.

    Article  CAS  PubMed  Google Scholar 

  5. Burnett AK, Goldstone AH, Stevens RMF, et al. Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet. 1998;351:700–708.

    Article  PubMed  CAS  Google Scholar 

  6. Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood. 1992;79:1924–1930.

    CAS  PubMed  Google Scholar 

  7. Linker CA, Ries CA, Damon LE, et al. Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol Blood Marrow Transplant. 2000;6:50–57.

    Article  PubMed  CAS  Google Scholar 

  8. Cassileth PA, Anderson J, Lazarus HN, et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol. 1993;11:314–319.

    Article  PubMed  CAS  Google Scholar 

  9. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332:217–223.

    Article  PubMed  CAS  Google Scholar 

  10. Ferrant A, Labopin M, Frassoni F, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission—a European Group for Blood and Marrow Transplantation study. Blood. 1997;90:2931–2938.

    PubMed  CAS  Google Scholar 

  11. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood. 2003;102:1232–1240.

    Article  PubMed  CAS  Google Scholar 

  12. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649–1656.

    Article  PubMed  CAS  Google Scholar 

  13. Mrózek K, Heinonen K, Bloomfield CD. Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. Int J Hematol. 2000;72:261–271.

    PubMed  Google Scholar 

  14. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322–2333.

    PubMed  CAS  Google Scholar 

  15. Keating S, Suciu S, de Witte T, et al. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplant. 1996;17:993–1001.

    PubMed  CAS  Google Scholar 

  16. Chalandon Y, Barnett MJ, Horsman DE, et al. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2002;8:435–443.

    Article  PubMed  Google Scholar 

  17. Gale RP, Horowitz MM, Weiner RS, et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant. 1995;16:203–208.

    PubMed  CAS  Google Scholar 

  18. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96:4075–4083.

    PubMed  CAS  Google Scholar 

  19. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763.

    CAS  PubMed  Google Scholar 

  20. Knechtli CJC, Goulden NJ, Hancock JP, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia Blood. 1998;92:4072–4079.

    PubMed  CAS  Google Scholar 

  21. Stirewalt DL, Guthrie KA, Beppu L, et al. Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. Biol Blood Marrow Transplant. 2003;9:206–212.

    Article  PubMed  Google Scholar 

  22. Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood. 2003;101:1698–1704.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Medicine, Osaka University Graduate School of Medicine, 2-2, Yamada-Oka, Suita City, 565-0871, Osaka, Japan

    Hiroyasu Ogawa, Kazuhiro Ikegame & Manabu Kawakami

  2. Division of Molecular Therapy, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo

    Satoshi Takahashi

  3. Bone Marrow Transplantation Team, Tokyo Metropolitan Komagome Hospital, Tokyo

    Hisashi Sakamaki

  4. Fifth Department of Internal Medicine, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka

    Takahiro Karasuno

  5. Department of Hematology, Meitetsu Hospital, Nagoya

    Hiroshi Sao

  6. Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital, Nagoya

    Yoshihisa Kodera

  7. Department of Hematology, Nagoya Daini Red Cross Hospital, Nagoya

    Noriyuki Hirabayashi

  8. Department of Medicine, Keio University School of Medicine, Tokyo

    Shinichiro Okamoto

  9. Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka

    Mine Harada

  10. Department of Internal Medicine, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima

    Koji Iwato

  11. Department of Hematology, Kanagawa Cancer Center, Kanagawa

    Atsuo Maruta

  12. Department of Hematology, Oncology, and Respiratory Disease, Okayama University Graduate Schools of Medicine and Dentistry, Okayama

    Mitsune Tanimoto

  13. Department of Pediatrics, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan

    Keisei Kawa

Authors
  1. Hiroyasu Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuhiro Ikegame
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manabu Kawakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Satoshi Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hisashi Sakamaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takahiro Karasuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroshi Sao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yoshihisa Kodera
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Noriyuki Hirabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shinichiro Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mine Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Koji Iwato
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Atsuo Maruta
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Mitsune Tanimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Keisei Kawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroyasu Ogawa.

Additional information

on behalf of the Japan Society for Hematopoietic Cell Transplantation

About this article

Cite this article

Ogawa, H., Ikegame, K., Kawakami, M. et al. Impact of Cytogenetics on Outcome of Stem Cell Transplantation for Acute Myeloid Leukemia in First Remission: A Large-Scale Retrospective Analysis of Data from the Japan Society for Hematopoietic Cell Transplantation. Int J Hematol 79, 495–500 (2004). https://doi.org/10.1532/IJH97.03166

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1532/IJH97.03166

Key words

Search

Navigation